Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 10/20 | 0.62 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 3/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.32 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29660812 | 0.78 | NLRP3 (0.63) | NLRP3P2RX3 | |
| SCHEMBL23950215 | 0.76 | NLRP3 (0.50) | NLRP3MALT1KCNH2ALDH1A1RAB9A | |
| SCHEMBL24076386 | 0.75 | NLRP3 (0.60) | NLRP3GPR139 | |
| SCHEMBL29030778 | 0.74 | NLRP3 (0.60) | NLRP3AADAT | |
| SCHEMBL29660806 | 0.73 | NLRP3 (0.59) | NLRP3RAB9AAADAT | |
| SCHEMBL29660868 | 0.72 | NLRP3 (0.57) | NLRP3 | |
| SCHEMBL29660890 | 0.71 | NLRP3 (0.75) | NLRP3P2RX3 | |
| SCHEMBL29660802 | 0.70 | NLRP3 (0.72) | NLRP3P2RX3 | |
| SCHEMBL24077196 | 0.68 | NLRP3 (0.59) | NLRP3MALT1GPR139 | |
| SCHEMBL23950217 | 0.65 | NLRP3 (0.52) | NLRP3MALT1KCNH2GPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043450-A1 | NEW COMPOUND | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-08 | — | — | US | disclosed |
| EP-4217347-A1 | NEW COMPOUNDS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| CN-116194445-A | New compounds | 詹森药业有限公司 | 2023-05-30 | — | — | CN | disclosed |
| WO-2022063896-A1 | NEW COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043450-A1 | NEW COMPOUND | NLRP3, NLRP1, PYCARD | NLRP3 1/4885P2RX3 42/4885MALT1 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.